Year: 2012
Type: article
Abstract: Asenapine (Sycrest) is an antipsychotic taken sub ‐ lingually for the treatment of moderate to severe manic episodes in bipolar disorder. In our New products review, Steve Chaplin presents the clinical data relating to its efficacy and adverse events and Dr Daniel Smith discusses its place in therapy. Copyright © 2012 Wiley Interface Ltd
Source: Prescriber
DOI: 10.1002/psb.942
Authors: Steve Chaplin, Daniel Smith
Language: English
Subfield: Psychiatry and Mental health
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
OpenAlex ID: W2022177595